NIR Diagnostics And LifeScan, Inc. Extend First Option Agreement
CAMPBELLVILLE, ON, Oct. 12 /CNW/ - NIR Diagnostics Inc. (TSX
Venture: NID), a leading-edge developer of handheld spectroscopy based medical
instruments, today announced that it has reached an agreement with Lifescan,
Inc., a leading maker of blood glucose monitoring systems, to extend by six
months the feasibility study and first option agreement previously announced
on January 3, 2006. The first option will now expire March 31, 2007 rather
than September 30, 2006.